SelfDecode uses the only scientifically validated genetic prediction technology for consumers. Read more

ACMG Secondary Findings Report with 30x Clinical‑Grade Whole Genome Sequencing

Your DNA hides serious health risks you won’t feel until it’s too late.

This Report uses the 30x whole genome sequencing and follows ACMG SF v3.3 list to reveal serious, medically actionable genetic risks years before symptoms appear.

It identifies inherited cancer, cardiovascular, and metabolic conditions that routine care often misses. Know what matters. Ignore the noise.

We will never share your data

We follow HIPAA and GDPR policies

We have World-Class Encryption & Security

People Love Us

Rated 4.7/5 from 750+ reviews

People Trust Us

200,000+ users, 2,000+ doctors & 100+ businesses

Discover Genetic Findings With 30x WGS

The ACMG‑Based Predisposition Report focuses on conditions where early action actually changes the future.

Using 30x clinical‑grade whole genome sequencing, it identifies ACMG secondary findings: pathogenic and likely pathogenic variants with strong evidence and clear management guidelines.

These are findings doctors use to guide targeted screening, specialist follow-up, and preventive care that can reduce complications and, in some cases, save lives.

Hereditary Cancer Syndromes: Identify inherited variants linked to breast, ovarian, colorectal, thyroid, and other cancers where early screening and prevention are proven to make a difference.
Cardiovascular Conditions: Reveal genetic risks tied to sudden cardiac death, cardiomyopathies, arrhythmias, and inherited cholesterol disorders that may require monitoring, medication, or specialist care.
Metabolic and Other Clinically Actionable Disorders: Uncover genetic risks affecting endocrine, hematologic, and metabolic pathways where early management can meaningfully improve outcomes.

What is ACMG Secondary Findings Report?

All report insights are derived from AI-powered analysis of your full genome according to the ACMG SF v3.3 for reporting of secondary findings in clinical exome and genome sequencing.

ACMG SF v3.3 is the 2025 update of the American College of Medical Genetics and Genomics (ACMG) recommended list of genes for reporting secondary findings in clinical exome and whole genome sequencing.

It defines a minimum set of 84 genes, including BRCA1, BRCA2, PALB2, APC, TP53, MLH1, MSH2, MSH6, PMS2, LDLR, APOB, PCSK9, MYH7, MYBPC3, KCNQ1, KCNH2, SCN5A, RYR2, HFE, RET, GLA, TSC1, TSC2 and others, where finding a pathogenic or likely pathogenic variant is considered medically actionable. Meaning early detection can change screening, treatment, or prevention.

The current ACMG Secondary Findings Working Group includes clinical geneticists, molecular and/or cytogenetics clinical laboratory directors, genetic counselors, cardiologists, a bioethicist, and a pediatrician who also serves as a patient advocate

Why Get the ACMG Secondary Findings Report?

Your genome may already contain high-risk variants that have nothing to do with your current symptoms. Ignoring them does not make them disappear.

This test is designed for people who want a clinical‑style ACMG secondary findings report based on 30x whole genome sequencing, without waiting for symptoms or relying on limited genotyping.

The ACMG framework focuses only on variants where medical action can reduce serious disease or premature death.

Identify High-Impact Genetic Risks

Surface pathogenic variants with strong clinical evidence across cancer, heart disease, and metabolic disorders.

Detect Risk Before Disease

Many ACMG conditions benefit from early imaging, labs, and surveillance long before symptoms begin.

Take Control of Precision Healthcare

Use your results to guide medical decisions, lifestyle changes, and informed conversations with healthcare providers.

People love us

Our customers say

Excellent

4.7 out of 5 based on 700+ reviews

How This Test Compares to Other Genetic Tests?

Not all genetic tests are designed to deliver ACMG Secondary Findings. Here’s how this 30x whole genome sequencing test differs from common alternatives:

Genotyping Kits
(e.g., Consumer DNA Tests)

Analyze a small fraction of your DNA using microarrays. Useful for ancestry and health traits, but not designed for comprehensive ACMG secondary findings or clinical‑grade risk assessment.

ACMG Panels
(Targeted Gene Tests)

Sequence only a predefined set of ACMG genes. Provide medically actionable results but do not capture full‑genome data, limiting future re‑analysis and additional insights beyond the panel.

SelfDecode ACMG‑Based Predisposition Report

Uses 30x clinical‑grade whole genome sequencing to read 100% of your DNA, then applies ACMG secondary findings criteria to report only pathogenic and likely pathogenic variants in ACMG‑recommended genes, while also unlocking a broader access to reanalysis.

Whole genome sequencing is the most comprehensive form of genetic testing, reading nearly 100% of your DNA across all chromosomes and ~20,000 protein‑coding genes at clinical‑grade depth.

Why this matters:

Rare genetic conditions, drug responses, and inherited disease risks often involve variants that chip‑based genotyping never captures. If earlier DNA tests haven’t given clear answers, it’s usually because they only sampled a small fraction of your genome.

We sequence your entire genome once with 30x clinical‑grade coverage—then focus on helping you understand the parts that actually matter for your health.

What the ACMG Secondary Findings Report Analyzes

The report focuses exclusively on pathogenic or likely pathogenic variants in ACMG-recommended genes, clinically actionable findings with strong evidence.

Hereditary Cancer Genes

Including BRCA1, BRCA2, MLH1, MSH2, APC, TP53, and others linked to preventable or surveillable cancers.

Cardiovascular and Arrhythmia Genes

Including MYH7, LMNA, SCN5A, LDLR, and additional genes associated with cardiomyopathy and sudden cardiac death.

Metabolic, Endocrine, and Other Actionable Conditions

Including familial hypercholesterolemia, iron overload disorders, and inherited metabolic pathway variants.

Only pathogenic and likely pathogenic variants are returned.
Variants of Uncertain Significance (VUS) are not included, following ACMG guidelines.

A simple, painless test that keeps unlocking new insights

Getting your genome sequenced is as easy as brushing your teeth. No blood draw, no clinic visit, no complicated logistics.

Your sample is processed with 30x clinical‑grade whole genome sequencing in our partner labs. Once your genome is sequenced, you never need to retest: every future SelfDecode report, from disease risk and ACMG findings to pharmacogenomics and longevity, is powered by the same complete dataset.

Step 1

We mail your SelfDecode DNA kit to your door.

Step 2

You gently swab the inside of your cheek for 1–2 minutes.

Step 3

You drop the prepaid package in the mail—and you’re done.

One test today. New reports for years.

Your 30x whole genome sequencing results become your lifelong genetic foundation. As SelfDecode releases new WGS‑based reports on emerging disease risks, medications, or longevity strategies, they can be unlocked from the same dataset, without another kit or appointment. Sequence once, then keep getting more from your DNA as science moves forward.

See Everything SelfDecode Has to Offer

Discover our full suite of health reports and features in one comprehensive guide.
Our Reports & Features Summary shows all the DNA results, tools, and insights you can get with SelfDecode.

Get Your ACMG Secondary Findings Report Today

You can wait for symptoms, or act now by accessing your full ACMG-Based Predisposition Report to uncover serious risks that standard testing will never show.

HSA/FSA Eligible

US Based Labs & Shipping

ACMG SF v3.3 Clinical Predisposition Report

SelfDecode DNA Kit Included

ACMG SF v3.3-Based Predisposition Report, covering 42 conditions
High-Coverage 30x Whole Genome Sequencing
SelfDecode Painless At-Home DNA Collection Kit
Full Lifetime Access to Your Genetic Information
Permanent Privacy-First Data Protection

$749

HSA & FSA Eligible

Not in the US?

Order Here

30x Whole Genome Advanced Package